Advertisement

Inhibition of Platelet Aggregation and Cardiovascular Effect of 5E-13,14-Didehydro Carboprostacyclin and 5E-13,14-Didehydro-20-Methyl-Carboprostacyclin

  • R. Ceserani
  • M. Grossoni
  • M. Bergamaschi
  • L. Zuliani
  • N. Mongelli
  • F. I. Pareti
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 54)

Abstract

After the discovery of prostacyclin (PGI2) in 1976 [1], the most potent inhibitor of human platelet aggregation in vitro [1] with simultaneous strong hypotensive effect in animals and humans [1, 2, 3], many efforts have been made to synthesize PGI2-derivatives that are chemically stable and which possibly have longer lasting action. The first goal has been reached easily enough and carboprostacyclin [4, 5], 10,10-difluoro-13,14-dehydroprostacyclin [6] and 16-methyl-18 yl carboprostacyclin (ZK-36374) [7] are the best known results of these efforts.

Keywords

Platelet Aggregation Arterial Blood Pressure Pulmonary Arterial Pressure Part Blood Bovine Coronary Artery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. Moncada, R. J. Gryglewski, S. Bunting, and J. R. Vane, An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation, Nature, 263: 663 (1976).PubMedCrossRefGoogle Scholar
  2. 2.
    R. J. Gryglewski, S. Bunting, S. Moncada, R. J. Flower, and J. R. Vane, Arterial walls are protected against deposition of platelet thrombi by a substances (Prostaglandin X) which they make from prostaglandin endoperoxides, Prostaglandins, 12: 685 (1976).PubMedCrossRefGoogle Scholar
  3. 3.
    A. Szczeklik, R. J. Gryglewski, R. Nizankowski, J. Musial, R. Pieton, and J. Mruk, Circulatory and antiplatelet effects of intravenous prostacyclin in healthy man, Pharm. Res. Commun., 10: 545 (1978).Google Scholar
  4. 4.
    B. J. R. Whittle, S. Moncada, F. Whiting, and J. R. Vane, Carbacyclin - a potent prostacyclin analog for the inhibition of platelet aggregation, Prostaglandins, 19: 605 (1980).PubMedCrossRefGoogle Scholar
  5. 5.
    R. Ceserani, M. Grossoni, D. Longiave, B. Mizzotti, 0. Pozzi, A. Dembinska-Kiec’, and S. Bianco, dl-9a-deoxy-9a-methylenePGI2 (a stable prostacyclin derivative): preliminary pharmacological data, Prostaglandins and Medicine, 5: 131 (1980).Google Scholar
  6. 6.
    Y. Hatano, J. Kohli, L. I. Goldberg, J. Fried, and M. M. Mehrotra, Vascular relaxing activity and stability studies of 10,10-difluoro-13,14-dehydroprostacyclin, Proc. Natl. Acad. Sci., USA, 77: 6846 (1980).PubMedCrossRefGoogle Scholar
  7. 7.
    K. Schrdr, H. Darius, R. Matzky, and R. Ohlendorf, The anti-platelet and cardiovascular actions of a new carbacyclin derivative (ZK 36374) equipotent to PGI2 in vitro, Naunyn-Schmiedeberg’s Arch. Pharmacol., 316: 252 (1981).Google Scholar
  8. 8.
    R. Ceserani, D. Longiave, M. Grossoni, M. Bergamaschi, C. Gondolfi, N. Mongelli, and L. Zuliani, 5E-13,14-didehydrocarboprostacyclin and 5E-13,14-didehydro-20-methyl-carboprostacyclin: preliminary data on inhibition of platelet aggregation and hypotensive effect, IRCS Medical Sciences, 9: 364 (1981).Google Scholar
  9. 9.
    D. J. Finney, Statistical Methods in Biological Assay (C. Griffin, ed. ), London (1972).Google Scholar
  10. 10.
    H. Grimm, Principles of statistical estimation, in: “Biostatistics in Pharmacology,” Vol. 2 (A. L. Delaunois, ed.), Pergamon Press, Ltd., Oxford, p. 611 (1973).Google Scholar
  11. 11.
    B. J. R. Baley, Tables of the Bonferroni “t” statistic, J.A.S.A. Vol. 72, No. 358, p. 469 (1977).Google Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • R. Ceserani
    • 1
  • M. Grossoni
    • 1
  • M. Bergamaschi
    • 1
  • L. Zuliani
    • 1
  • N. Mongelli
    • 1
  • F. I. Pareti
    • 2
  1. 1.R & S, Farmitalia Carlo ErbaMilanoItalia
  2. 2.Clinica Medica IIIUniversità di MilanoItalia

Personalised recommendations